Boehringer's Ofev Faces Efficacy Hurdle For SSc-ILD Indication At US FDA Advisory Cmte.

The Arthritis Advisory Committee will give its take on Boehringer Ingelheim's forced vital capacity data as the drugmaker seeks to land add an indication for a rare lung disease to the label of its tyrosine kinase inhibitor Ofev.